Skye Bioscience, Inc. (SKYE) earnings
SKYE earnings moved a median of +0.57% by the close. Quarterly and annual SKYE reports and results, each read against the price at its own news timestamp. Back to the SKYE overview →
22 measured SKYE earnings events.
Where these SKYE earnings landedvs 22 measured SKYE earnings reactions
| Middle 50% of SKYE earnings reactions | -4.74% to +4.48% |
|---|---|
| Median reaction (to close) | +0.57% |
| Measured reactions | 22 |
Point-in-time · zero look-ahead
Half of the 22 SKYE earnings events with a measured close landed between -4.74% and +4.48%; 55% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Skye Bioscience, Inc. For: Jun 30 | SEC filing · Form 10-Q | -17.44% | -41.69% | |
| UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update | Press release | +0.01% | -1.77% | |
| Form 10-Q Skye Bioscience, Inc. For: Mar 31 | SEC filing · Form 10-Q | -5.47% | -9.61% | |
| Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update | Press release | -5.47% | -9.61% | |
| Form 10-K Skye Bioscience, Inc. For: Dec 31 | SEC filing · Form 10-K | +1.49% | +9.29% | |
| Form 10-Q Skye Bioscience, Inc. For: Sep 30 | SEC filing · Form 10-Q | +1.21% | +4.29% | |
| Skye Bioscience Reports Third Quarter 2025 Financial Results and Business Update | Press release | +1.21% | +4.29% | |
| Skye Bioscience to Announce Third Quarter 2025 Financial Results and Business Update on November 10, 2025 | Press release | +1.39% | +4.86% | |
| Form 10-Q Skye Bioscience, Inc. For: Jun 30 | SEC filing · Form 10-Q | -0.08% | +0.57% | |
| Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update | Press release | -0.08% | +0.57% | |
| Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025 | Press release | +0.14% | +0.84% | |
| Form 10-Q Skye Bioscience, Inc. For: Mar 31 | SEC filing · Form 10-Q | +2.10% | -4.74% | |
| Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity | Press release | +2.10% | -4.74% | |
| Form 10-K Skye Bioscience, Inc. For: Dec 31 | SEC filing · Form 10-K | +7.85% | +17.80% | |
| Form 10-Q Skye Bioscience, Inc. For: Sep 30 | SEC filing · Form 10-Q | -3.44% | -4.20% | |
| Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights | Press release | -3.44% | -4.20% | |
| Skye Bioscience to Announce Third Quarter 2024 Results | Press release | +1.70% | +4.71% | |
| Form 10-Q Skye Bioscience, Inc. For: Jun 30 | SEC filing · Form 10-Q | +1.14% | +4.54% | |
| Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights | Press release | +1.14% | +4.54% | |
| Form 10-Q Skye Bioscience, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.00% | +2.79% | |
| Form 10-K Skye Bioscience, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.00% | -8.74% | |
| Form 10-Q Skye Bioscience, Inc. For: Sep 30 | SEC filing · Form 10-Q | -2.94% | -7.35% |
Keep exploring
More SKYE: analyst actions → · SEC filings → · SKYE overview →